Cingulate Inc.

NasdaqCM CING

Cingulate Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Cingulate Inc. EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: CING

Cingulate Inc.

CEO	Dr. Shane J. Schaffer Pharm.D.
IPO Date	Dec. 8, 2021
Location	United States
Headquarters	1901 West 47th Place
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Key trends

Past 5 years